Publications by authors named "N P A Peter Zuithoff"
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluates the effectiveness and longevity of treatments (dupilumab, methotrexate, and cyclosporine A) for pediatric patients aged 2-17 with severe atopic dermatitis across five centers in the Netherlands from 2013-2023.
- - Out of 502 treatment episodes analyzed, dupilumab showed the highest drug survival rates over three years (84.1% at one year, 72.3% at two, and 62.0% at three), compared to significantly lower rates for methotrexate and cyclosporine A.
- - The main reason for discontinuing treatment was ineffectiveness, especially noted with cyclosporine A, while factors like treatment
Article Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
The Japanese Esophageal Society classification for prediction of superficial esophageal squamous cell neoplasia invasion depth: Validation in a Western population.
United European Gastroenterol J
October 2024
Article Synopsis
- - The JES microvessel classification was proposed for evaluating early esophageal squamous cell neoplasia (ESCN) based on the assessment of intrapapillary capillary loops, aiming to determine eligibility for endoscopic resection in Western patients.
- - A study analyzed 113 Western ESCN lesions with assessments from nine endoscopists of different experience levels, revealing good interobserver agreement among experts but only moderate agreement among residents-in-training.
- - The overall accuracy of the classification was found to be low, especially among Western endoscopists and trainees, with highlighted limitations in effectively predicting invasion depth, though experienced endoscopists showed some success in identifying superficial layers without B3 vessels.